Background: Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, leading to impaired chloride and bicarbonate ion transport. This defect results in thick, viscous mucus accumulation, primarily affecting the respiratory, gastrointestinal, and reproductive systems. The disease is characterized by chronic infections, inflammation, and progressive organ dysfunction, significantly impacting patients__ampersandsignrsquo; quality of life and longevity. Methods: A comprehensive review of current literature was conducted, focusing on the pathophysiology of CF, including the role of CFTR mutations, the organ-specific consequences of these defects, and the latest advances in therapeutic strategies. Sources included peer-reviewed articles, clinical trials, and guidelines from cystic fibrosis research organizations. Results: The pathophysiology of CF reveals a complex interplay of mucus obstruction, bacterial colonization, and inflammatory responses, particularly in the lungs, leading to chronic respiratory issues and progressive lung damage. Gastrointestinal complications such as pancreatic insufficiency and malabsorption, as well as reproductive challenges, are common. Recent advancements in CF treatment, particularly CFTR modulators, have shown significant promise in improving lung function and patient outcomes. Ongoing research into gene therapy and anti-inflammatory treatments is exploring ways to target the underlying causes of CF more effectively. Conclusions: Understanding the intricate pathophysiology of cystic fibrosis is essential for developing effective therapies. While current treatments have improved management and outcomes, continued research into targeted therapies and innovative treatments holds promise for enhancing the quality of life and life expectancy for CF patients.